FDA clearance of the individual peanut component tests brings these new in vitro allergy tests to clinicians nationwide.
The uKnow Peanut Test reports specific IgE results to five FDA cleared peanut allergen components in addition to a laboratory developed test.
Physicians can now detect the allergic sensitisation to the specific allergen components within the whole peanut to help assess the risk that a patient will experience a severe anaphylactic reaction upon exposure to peanuts.
David Esposito, president and general manager of Phadia US, said: “With the introduction of the uKnow Peanut Test, Phadia is equipping clinicians with the ability to diagnose their patients’ likely reaction to peanut exposure more accurately. Armed with this knowledge, the patient and physician together can make a more informed assessment and decide on an appropriate management plan.”
The uKnow Peanut Test will be available exclusively through Pirl. This launch will provide Phadia with the ability to aggregate national data on peanut allergy, and support the broad assessment and interpretation of peanut component results across all regions of the country.
Source: Phadia
© FoodBev Media Ltd 2024